Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNV-201 in low-risk myelodysplastic syndrome
NCT06465160Phase 1Recruiting
- Sponsor
- Minovia Therapeutics
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MNV-BM-PLC in myelodysplastic syndrome (MDS), sponsored by Minovia Therapeutics. Primary endpoint: Occurrence of treatment-related adverse events at 1 year. Started May 2024; status: recruiting.
02
Drugs
MNV-BM-PLC
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06465160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465160.